Flares after Hydroxychloroquine Reduction or Discontinuation: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Ann Rheum Dis. 2021:annrheumdis-2021-221295. Epub ahead of print
Evidence suggests that hydroxychloroquine (HCQ) reduction/withdrawal may be safe in some stable patients, but in other settings it may be associated with disease flare. Almeida-Brasil, et al. sought to evaluate SLE flares following HCQ reduction or discontinuation versus HCQ maintenance. Their data suggest that maintaining HCQ was associated with a lower flare risk than reduction or discontinuation, even in patients with low disease activity or remission.
Efficacy and Safety of Ustekinumab in Patients with Active Systemic Lupus Erythematosus: Results Through 2 Years of an Open-Label Extension in a Phase 2 Study
J Rheumatol. 2021. Epub ahead of print
Phase II data demonstrate clinical benefit in global and organ-specific SLE-activity measures with ustekinumab through 2 years with no new or unexpected safety findings.
Clin Exp Dermatol. 2021. Epub ahead of print
Phase II data and two individual case reports have shown significant improvement in signs and symptoms of disease in patients with systemic lupus erythematosus (SLE) receiving baricitinib. This case study by Joos et al. reports a further patient with SLE treated successfully with baricitinib.
2019-EULAR/ACR Classification Criteria Domains at Diagnosis: Predictive Factors of Long-Term Damage In Systemic Lupus Erythematosus
Clin Rheumatol. 2021. Epub ahead of print
Single-centre, retrospective analysis identifying that specific domains in the 2019-EULAR/ACR criteria at diagnosis are associated with long-term organ-specific damage, particularly renal and neuropsychiatric harm.
Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus: A Randomized Controlled Trial
Ann Intern Med. 2021. Epub ahead of print. doi: 10.7326/M21-2078.
Preliminary evidence suggests that belimumab after rituximab could be developed as a therapeutic strategy for patients with Systemic Lupus Erythematosus (SLE) refractory to conventional therapy.
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
Arthritis Rheumatol. 2021;73(10):183–46
Despite evidence of strong pathway inhibition, findings from a Phase 2 study of patients with moderate-to-severe SLE indicate that fenebrutinib did not demonstrate a treatment benefit over placebo.
What Are The Benefits And Harms Of Belimumab For Patients With Systemic Lupus Erythematosus?: A Cochrane Review Summary With Commentary
Int J Rheum Dis. 2021;24(10):1331–3
Biologic therapies, particularly belimumab, show promising results in the clinical management of SLE.
B-cell Depletion With Obinutuzumab for the Treatment of Proliferative Lupus Nephritis: A Randomised, Double-blind, Placebo-controlled Trial
Ann Rheum Dis. 2021. doi:10.1136/annrheumdis-2021-220920
Phase 2 study data support the use of obinutuzumab in proliferative lupus nephritis (LN) being further evaluated in a global Phase 3 study.
Long-term Outcome Of A Randomised Controlled Trial Comparing Tacrolimus With Mycophenolate Mofetil As Induction Therapy For Active Lupus Nephritis
Ann Rheum Dis 2020;79:1070–6
Tacrolimus is non inferior to MMF as an induction therapy for LN.
N Engl J Med 2020:211–20
Morand et al demonstrate a greater BICLA response at Week 52 for patients treated with anifrolumab versus those treated with placebo.